Randomized Phase III Trial of Paclitaxel +Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Apr 2017
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 02 Nov 2015 Results published in the Journal of Clinical Oncology
- 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2013 Primary endpoint 'Complete-pathological-response-rate' has not been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History